Potential serious reactions w/ MAOIs. May inhibit metabolism of thioridazine. May lead to serotonin-associated effects w/ serotonergic medicinal/herbal products (including L-tryptophan, triptans, tramadol, linezolid, SSRIs, SNRIs, lithium & St. John's wort prep). CNS-active medicinal products (eg, antiepileptics, antidepressants, antipsychotics, anxiolytics, sedative hypnotics). Reduced clearance w/ CYP2D6, CYP3A4 & flavin monooxygenase 1 inhibitors. Increased exposure w/ potent (eg, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir & atazanavir) & moderate (eg, erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem) CYP3A4 inhibitors; potent CYP2D6 inhibitors. Possible reduced orthostatic tolerance w/ PDE5 inhibitors & α-adrenergic receptor antagonists. Increased plasma conc of desipramine & other drugs metabolized by CYP2D6. Decreased AUCinf
of midazolam. Warfarin (chronic therapy). Increased somnolence & decreased alertness w/ ethanol.